Lunit

328130.KQ

36.04 USD

-2.14

-5.61%

Overview

Last close

36.04 usd

Market cap

1.04B usd

52 week high

69.62 usd

52 week low

23.39 usd

Target price

41.64 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

26.0063

Price/Book Value

9.5274

Enterprise Value

1.13B usd

EV/Revenue

29.1035

EV/EBITDA

-45.3273

Key financials

Revenue TTM

38.90M usd

Gross Profit TTM

38.90M usd

EBITDA TTM

-43.06M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

295.15M usd

Net debt

320693.32 usd

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.